Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01237340 · ClinicalTrials.gov registry record · Phase 3
Saizen® Solution for Injection Adult Growth Hormone Deficiency (GHD) Immunogenicity Study
A Phase 3 study, sponsored by EMD Serono.
- Terminated
- Registry status
- Phase 3
- Development phase
- 59
- Enrollment target
NCT01237340 is a Phase 3 study that was terminated before completion, run by EMD Serono. The registered enrollment target is 59 participants.
The verdict
NCT01237340, a Phase 3 study, was terminated before completion, sponsored by EMD Serono.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 59 participants
- Enrollment target
Study Summary
To assess the immunogenicity of Saizen® solution for injection in adult subjects with documented Growth Hormone Deficiency (GHD).
Interventions
- DRUG Saizen®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2010-10 |
| Est. Completion | 2011-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01237340
The ClinicalTrials.gov registry entry for NCT01237340 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Saizen® is the first listed.
NCT01237340 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01237340 about?
NCT01237340 is a clinical study titled "Saizen® Solution for Injection Adult Growth Hormone Deficiency (GHD) Immunogenicity Study". To assess the immunogenicity of Saizen® solution for injection in adult subjects with documented Growth Hormone Deficiency (GHD).
What is the current status of trial NCT01237340?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 59 participants. The study started on 2010-10. Estimated completion is 2011-12.
What interventions are being tested in trial NCT01237340?
The interventions under investigation include: Saizen® (DRUG).
Who is sponsoring clinical trial NCT01237340?
This trial is sponsored by EMD Serono, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.